AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

$95.14+0.59 (+0.62%)

Delayed as of 21 Nov 2024, 09:57 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AXSM Price Action

Last 7 days

-3.3%

Last 30 days

3.3%

Last 90 days

8.5%

Trailing 12 Months

59.8%

AXSM RSI Chart

AXSM Valuation

Market Cap

4.6B

Price/Earnings (Trailing)

-14.74

Price/Sales (Trailing)

13.54

EV/EBITDA

-15.24

Price/Free Cashflow

-34.5

AXSM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AXSM Fundamentals

AXSM Revenue

Revenue (TTM)

338.5M

Rev. Growth (Yr)

81.27%

Rev. Growth (Qtr)

20.19%

AXSM Earnings

Earnings (TTM)

-311.0M

Earnings Growth (Yr)

-3.86%

Earnings Growth (Qtr)

18.58%

AXSM Profitability

EBT Margin

-91.97%

Return on Equity

-334.73%

Return on Assets

-55.38%

Free Cashflow Yield

-2.9%

AXSM Investor Care

Shares Dilution (1Y)

2.42%

Diluted EPS (TTM)

-6.59

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	251.0M	291.5M	338.5M	0
2023	144.6M	182.5M	223.4M	270.6M
2022	0	0	0	50.0M
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	287.1K	356.9K
2018	209.7K	212.3K	214.8K	217.4K
2017	0	0	0	207.1K
2016	1.8M	1.4M	914.0K	474.3K
2014	0	0	0	2.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CEO	Dr. Herriot Tabuteau M.D.
WEBSITE	axsome.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	422

Axsome Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Axsome Therapeutics Inc? What does AXSM stand for in stocks?

AXSM is the stock ticker symbol of Axsome Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axsome Therapeutics Inc (AXSM)?

As of Wed Nov 20 2024, market cap of Axsome Therapeutics Inc is 4.58 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers.

Is Axsome Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AXSM is over valued or under valued. Whether Axsome Therapeutics Inc is cheap or expensive depends on the assumptions which impact Axsome Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXSM.

What is Axsome Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, AXSM's PE ratio (Price to Earnings) is -14.74 and Price to Sales (PS) ratio is 13.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXSM PE ratio will change depending on the future growth rate expectations of investors.